Results (i) RF_{CSA} decreased significantly, ($-17.7 \pm 12.1\%$ [$p < 0.001$]), but underestimated muscle loss determined by either $Fibre_{CSA}$ ($-10.3 \pm 10.9\%$ vs. $-17.5 \pm 30.2\%$, $p = 0.31$), or assessment of protein/DNA ratio ($-10.3 \pm 10.9\%$ vs. $-29.5 \pm 41.5\%$, $p = 0.03$). (ii) Fall in RF_{CSA} was greater in multi- than single-organ failure ($-21.5 \pm 10.5\%$ vs $-7.2 \pm 9.7\%$ respectively, $p < 0.0001$), even by day 3 ($-8.7 \pm 16.3\%$ vs $-1.8 \pm 9.6\%$, $p < 0.01$). Those suffering ≥ 4 organ were worst affected ($-26.3 \pm 12.0\%$ vs $-19.5 \pm 9.4\%$ for 2–3 organ failure, $p < 0.01$). (iii) Histopathological myofibre necrosis occurred in $>50\%$ (17/33) of subjects. (iv) Protein synthesis was depressed, to levels observed in fasted controls ($0.035 \pm 0.018\%/hr$ vs. $0.039 \pm 0.011\%/hr$ respectively, $p = 0.57$). Synthesis rates increased by day 7 ($0.076 \pm 0.066\%/hr$, $p = 0.07$) to levels associated with healthy fed controls ($0.065 \pm 0.018\%/hr$, $p = 0.30$). These effects were independent of nutritional calorie and protein load received. (v) Protein breakdown remained elevated throughout (8.5 ± 5.7 to 10.6 ± 5.7 mmol phe/min/IBW, $p = 0.4$). (vi) Principal component analysis of patterns of intracellular signalling suggested an orchestrated programme of increased breakdown ($r = -0.83$, $p = 0.005$) and depressed synthesis ($r = -0.69$, $p = 0.041$).

Conclusions Skeletal muscle wasting (defined for the first time by three independent measures) (1) occurs early and rapidly in critical illness and (2) is greatest in those with multi-organ failure. Suppression of protein synthesis and increases in catabolism (isotope uptake and intracellular signalling data) were shown, for the first time, to underpin these changes. Importantly, these overall effects appear independent of feeding status, and also to be commonly associated with (previously unrecognised) myonecrosis.

ZAP is a National Institute of Health Research Research Fellow, and has received funding from the European Society of Intensive Care Medicine, Guys and St Thomas Comprehensive Biomedical Research Centre and the Whittington Hospital NHS Trust.

T4

MUTATIONS IN BMPR-II PROMOTE INFLAMMATION VIA ALTERED SUPEROXIDE SIGNALLING: INSIGHTS INTO THE MECHANISMS UNDERLYING PULMONARY ARTERIAL HYPERTENSION

doi:10.1136/thoraxjnl-2012-202678.004

¹E Soon, ¹A Crosby, ²M Southwood, ²J Pepke-Zaba, ¹P Upton, ¹NW Morrell. ¹University of Cambridge, Cambridge, UK; ²Papworth Hospital NHS Trust, Cambridge, UK

Introduction Although the presence of inflammation is well recognised in pulmonary arterial hypertension (PAH), the underlying mechanisms remain poorly understood. Mutations in the bone morphogenetic protein type II receptor gene, *BMPR2*, underlie the majority of heritable and a significant fraction of idiopathic PAH. Here, we sought to determine whether loss of *BMPR2* was directly associated with inflammation, the underlying mechanisms, and possible therapeutic interventions.

Methods The initial approach employed human and mouse pulmonary arterial smooth muscle cells (PASMCs) from controls and subjects with a mutation in *BMPR2*. Cells were studied at baseline and in response to lipopolysaccharide (LPS), in the presence or absence of pharmacological inhibitors of known pro-inflammatory pathways. Cytokines were measured by ELISA. Reactive oxygen species were measured using dihydroethidium staining. For *in vivo* studies, we employed the heterozygous null *bmpr2* mouse (*bmpr2*^{+/−}) and wild-type littermates.

Results Chronic low dose LPS resulted in a marked elevation of right ventricular systolic pressure to ~ 40 mmHg in *bmpr2*^{+/−} mice, but not in wild-type mice (Fig. 1). *In vitro* studies showed that mouse *bmpr2*^{+/−} and human *BMPR2*^{mut} PASMCs produced more IL-6 and IL-8 at baseline and after stimulation with LPS. For example, *bmpr2*^{+/−} PASMCs produced 1533 ± 280 pg/ml of IL-6 (versus 341 ± 10 pg/ml in controls, $P < 0.01$) after LPS stimulation. Reduced *BMPR2* was also associated with increased phospho-STAT3 levels and an abnormal pro-proliferative response to IL-6. Acute administration of LPS to the *bmpr2*^{+/−} mouse reproduced these results *in vivo*, with increased lung and serum IL-6 and IL-8. The link between reduced *BMPR2* and increased cytokine expression was found to be associated with increased superoxide generation and loss of extracellular superoxide dismutase (SOD3). Treatment of *BMPR2* deficient PASMCs with the superoxide dismutase mimetic, Tempol, normalised the exaggerated secretion of IL-6 and IL-8. Co-administration of Tempol prevented the PAH phenotype in *bmpr2*^{+/−} mice exposed to low dose LPS (Fig. 1).

Conclusions We have determined a novel link between *BMPR2* loss and increased expression of pro-inflammatory cytokines, which is dependent on mishandling of superoxide. Our results suggest that pro-inflammatory stimuli may represent disease-provoking triggers for patients with *BMPR2* deficiency. Promotion of SOD3 activity may represent a novel therapeutic approach in PAH.

Time course of acute muscle loss during ICU stay: stratification by organ failure

$\Delta RFCSA\%$ = change in rectus femoris cross sectional area, Organ failure defined by cumulative scores of ≥ 2 per system in the Sequential Organ Failure Assessment (SOFA). Statistical analysis done by repeated measures 2 way analysis of variance, * denotes significant change from Day 1 in patients in Multi-Organ Failure, and in comparison to Single-Organ Failure

Abstract T3 Figure 1

Fig.1: *Bmpr2*^{+/-} mice exhibit increased right ventricular systolic pressures after chronic LPS administration. This is not seen in the wild-type, and is prevented by co-administration of Tempol, a superoxide dismutase mimetic.

Key:

* $p < 0.05$ compared to untreated *bmpr2*^{+/-} mice

$p < 0.01$ compared to wild-type mice with LPS

Abstract T4 Figure 1

T5 SAMPLING AIRWAY MUCOSAL LINING FLUID IDENTIFIES ROLES FOR IL-33 AND MULTIPLE INFLAMMATORY PATHWAYS IN VIRUS-INDUCED ASTHMA EXACERBATIONS

doi:10.1136/thoraxjnl-2012-202678.005

¹DJ Jackson, ¹M Trujillo-Torralbo, ¹J Footitt, ²B Shamji, ¹J del-Rosario, ¹A Telcian, ²T Hunt, ³D Hunt, ¹P Mallia, ⁴OM Kon, ²M Edwards, ²J Westwick, ¹TT Hansel, ¹SL Johnston. ¹National Heart and Lung Institute, Imperial College London, MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK; ²Novartis Institute for Biomedical Research, UK; ³Hunt Developments Ltd, Midhurst, UK; ⁴Imperial College NHS Trust

Rhinovirus (RV) infection is the most common cause of asthma exacerbations (AE), however mechanisms are poorly understood. Conventional sampling techniques such as bronchoalveolar lavage dilute many cytokines below limits of detection and consequently it has not been possible to measure key mediators of Th1, Th2 and Th17 pathways during virus-induced AE's. In addition, IL-33, an epithelial-derived alarmin, has recently been shown to be essential for mouse virus-induced airway hyperresponsiveness, however the relationship between IL-33 and exacerbations in human asthma remains unknown. Using the human model of experimental RV induced AE along with novel techniques to sample upper and lower airway mucosal lining fluid (MLF) we investigated the roles of IL-33 and several other prominent cytokines in virus-induced AE's.

Methods 32 mild-to-moderate asthmatics and 14 healthy subjects were inoculated nasally with RV-16. Symptom scores were recorded daily. Bronchoscopies were performed 2 weeks prior to inoculation and on d4 post-inoculation. Novel techniques to sample MLF called 'bronchosorption' and 'nasosorption' were performed. Cytokines were measured in both bronchial and nasal samples at baseline and on d4 with further nasal sampling on days 2, 3, 5, 7, 10 and 42.

Results In asthma, nasal IL-4, -5, -13, -17, -33, and IFN- γ levels were significantly increased during infection compared to baseline (all $P < 0.001$). IL-33 and Th2 cytokines but not IFN- γ or IL-17 were increased in asthma compared to healthy subjects ($P < 0.01$). In the asthmatic lung, relationships between bronchial IL-33 ($P < 0.05$),

IL-13 ($p < 0.05$), IL-5 ($p = 0.059$) and chest symptom scores were observed. Bronchial levels of these cytokines correlated with nasal levels during infection ($p < 0.05$) whilst baseline nasal levels of Th2 cytokines correlated strongly with infection levels ($p < 0.001$).

Conclusion Sampling MLF permits the direct measurement of previously undetectable mediators across multiple inflammatory pathways. Increased IL-33 and Th2 induction are associated with increased AE severity. IL-33 correlated strongly with Th2 cytokine levels and may represent a novel target for the treatment of virus-induced AE's. In addition, nasal Th2 inflammation correlated with bronchial levels whilst baseline levels predicted the magnitude of Th2 induction during the AE. Therefore it may be possible to use nasosorption to guide therapy with anti-IL-5 and anti-IL-13 mAb treatments.

T6 THROMBOCYTOSIS IS ASSOCIATED WITH INCREASED SHORT AND LONG TERM MORTALITY AFTER EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

doi:10.1136/thoraxjnl-2012-202678.006

MT Harrison, P Short, P Williamson, A Singanayagam, AR Akram, JD Chalmers, S Schembri. NHS Tayside, Dundee, UK

Introduction There is increasing evidence suggesting that platelets play a significant role in inflammation in addition to their established role in thrombosis. Systemic inflammation is linked to poor short and long term outcomes in COPD. Increased platelet activation has been reported in acute exacerbations of COPD (AECOPD). We investigated whether thrombocytosis is associated with poor outcomes following AECOPD.

Methods A prospective observational cohort study of patients hospitalised with AECOPD was performed. The dataset consists of patients >40 years, with spirometrically confirmed COPD admitted with exacerbations between 2009–2011. Platelet count was recorded on admission. The primary outcome was in-hospital mortality with secondary outcomes of 1 year all-cause mortality, cardiovascular events and mortality. Analyses were conducted using co-proportional hazards regression after adjustment for demographics, co-morbidities, chronic treatments and severity of exacerbations.

Results 1343 patients (49% male) were included with a median age of 72 years (interquartile range 63–79 years). 157 patients (11.7%) had thrombocytosis (platelet count $> 400 \times 10^9$ cells/mm³).

Thrombocytosis correlated with established markers of poor outcome in COPD, including hypoalbuminaemia (34 IQR 31–38 vs 37 33–40, $p < 0.0001$), low BMI (BMI < 18.5 in 14.6% vs 9.1%, $p = 0.03$) and frequent exacerbations in the previous year (mean 1.42 standard deviation (SD) 1.9 vs mean 1.1 SD 1.8, $p = 0.02$).

Thrombocytosis was significantly associated with in-hospital mortality: Hazard ratio (HR) 1.96 (1.15–3.32) and 1 year mortality after discharge HR 1.48 (1.12–1.97). The relationships with cardiovascular hospitalisation HR 1.17 (0.84–1.64) and 1 year cardiovascular mortality HR 1.33 (0.82–2.14) were not statistically significant.

To determine if the increased risk associated with thrombocytosis was potentially modifiable, we studied whether antiplatelet treatment (chronic prescription of aspirin or clopidogrel) would attenuate the risks associated with thrombocytosis. Anti-platelet treatment was associated with reduced 1 year mortality HR 0.75 (0.59–0.97) with a trend towards reduced in-hospital mortality HR 0.66 (0.40–1.09), cardiovascular hospitalisation HR 0.81 (0.61–1.08) and cardiovascular death HR 0.85 (0.57–1.26).

Conclusion Thrombocytosis was associated with increased in-hospital and 1 year mortality. This relationship was only partly attributable to increased cardiovascular mortality. Anti-platelet medications correlated with significantly lower 1 year mortality and may have a protective role to play in COPD.